Compare LKFN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | CDNA |
|---|---|---|
| Founded | 1872 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2009 | 2007 |
| Metric | LKFN | CDNA |
|---|---|---|
| Price | $61.60 | $29.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $67.00 | $28.00 |
| AVG Volume (30 Days) | 249.4K | ★ 895.4K |
| Earning Date | 04-27-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 1.04 | 0.05 |
| Revenue | $985,000.00 | ★ $48,324,000.00 |
| Revenue This Year | $15.50 | $16.01 |
| Revenue Next Year | $5.51 | $11.31 |
| P/E Ratio | ★ $58.25 | $574.40 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $54.36 | $10.96 |
| 52 Week High | $69.38 | $30.00 |
| Indicator | LKFN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 66.07 |
| Support Level | $58.27 | $27.32 |
| Resistance Level | $63.10 | $30.00 |
| Average True Range (ATR) | 1.50 | 1.17 |
| MACD | -0.11 | -0.09 |
| Stochastic Oscillator | 54.48 | 87.01 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.